Andrew Bialecki

Co-CEO Andrew Bialecki sold 212,529 shares of KVYO at $14.61 via scheduled 10b5-1 plan; stock down 26.1% in 30 days.

Andrew Bialecki, Co-Chief Executive Officer, sold 212,529 shares at $14.61 on 2026-05-26 under a pre-arranged 10b5-1 trading plan adopted on 2025-05-20, meaning this was a scheduled transaction rather than discretionary timing. The sale occurred as the stock trades at $14.74 current price, down 59.9% from its 52-week high and off 26.1% over the prior 30 days. His prior five trades at KVYO have averaged negative 30-day and 90-day returns, ranging from -1.7% to -17.5% in the 30-day window. Klaviyo reported latest-quarter revenue of $358,005,000.00 with annual revenue growth of 31.6%, but the company was unprofitable over its most recent full fiscal year, creating a divergence between growth trajectory and current profitability that warrants attention to the fundamentals underlying the stock's recent weakness.

Co-CEO Bialecki sells entire 200.0K share stake in KVYO for $2,976,000.00 via 10b5-1 plan; stock down -24.7% in 30 days.

Bialecki Andrew, Co-Chief Executive Officer, executed a complete liquidation of his 200,000 share position at $14.88 per share on 2026-05-19, reducing holdings from 200.0K shares to 0 shares. This transaction is scheduled under a 10b5-1 trading plan adopted on 2025-05-20 and is not discretionary. The stock has declined -24.7% over the 30 days following the sale and stands at $15.11, down -58.9% from the 52-week high of $36.76. His prior five sales at KVYO show mixed post-transaction performance, with 30-day returns ranging from -18.1% to +3.4%, while his cross-ticker track record across 20 prior sells shows an average 90-day return of -23.7%. The company posted $358.0M in revenue (latest quarter) with +31.6% annual revenue growth, though it remains unprofitable on a full-year basis with negative net income.

Klaviyo Co-CEO Bialecki sells 200.0K shares in 2 transactions for $2.9M, reducing holdings to 0 under 10b5-1 plan

Co-Chief Executive Officer Andrew Bialecki executed 2 separate sales totaling 200,000 shares for $2,921,928.84 under a 10b5-1 trading plan adopted on 2025-05-20, leaving him with 0 shares post-transaction — a -100.0% reduction from his pre-transaction holdings of 200,000 shares. Because this is a scheduled transaction, the execution timing relative to price action is not a property of this trade. The stock currently sits at $14.34, down -62.0% from its 52-week high and -15.4% over 30 days and -22.9% over 90 days, context that reflects market conditions at the time of plan execution but not discretionary judgment. On the fundamentals side, Klaviyo reported latest-quarter revenue of $358.0M and net income of $9.0M, though the company was unprofitable over its most recent full fiscal year.

Co-CEO Bialecki sells 200,000 KVYO shares at $17.19 avg; stock -22.8% in 90d, -50.9% from 52w high

Andrew Bialecki, Co-Chief Executive Officer, executed 2 separate sales totaling 200,000 shares for $3,437,113.90 on 2026-04-14, at an average price of $17.19. The stock has since declined -22.8% over 90 days and trades -50.9% from its 52-week high of $37.50. However, this filing contains a derivative-conversion transaction, so the shares sold represent a conversion of derivative securities rather than an open-market position reduction. Klaviyo's fundamentals show revenue of $310,880,000.00 in the latest quarter with annual revenue growth of +31.6%, but the company was unprofitable with net income of $-426,000.00, indicating ongoing losses despite strong top-line growth. The transaction's timing relative to recent price weakness and the company's profitability challenges warrants examination, though the conversion mechanism distinguishes this from a discretionary open-market sale.

Co-CEO Bialecki sold 200.0K shares of KVYO at $18.63; stock down -52.6% from 52-week high, trades at $17.79

Bialeki Andrew, Co-Chief Executive Officer, sold 200,000 shares (200.0K shares) at $18.63 on 2026-04-07, eliminating his common stock position and raising $3,726,000.00 ($3.7M). This sale occurs in a deteriorating stock environment: KVYO is down -52.6% from its 52-week high of $37.50 and has declined -37.8% over 90 days, with the current price at $17.79 trading below the sale price. The timing is notable given the insider's cross-ticker track record shows 20 prior sales with a 100.00% well-timed rate at the 90-day mark, though at KVYO specifically, prior near-term outcomes remain unmeasured. The company backdrop shows revenue of $310,880,000.00 ($310.9M) with annual growth of +31.6%, but unprofitability persists, with net income of $-426,000.00 ($-426.0K) in the latest quarter. The sale of the entire common stock tranche, combined with the stock's sharp recent decline and the company's inability to reach profitability despite strong growth, warrants attention to whether this signals executive reassessment of near-term prospects.

Co-CEO Bialecki sold 200,000 (200.0K shares) of KVYO at $19.42; now holds zero shares via derivative conversion.

Andrew Bialecki, Co-Chief Executive Officer, sold 200,000 shares of Klaviyo at $19.42 on 2026-03-31, realizing $3,884,000. The transaction involves a derivative conversion (Form 4 Table II), meaning the shares_after value of zero does not represent a complete position exit—the insider's actual holdings in derivative securities are not yet populated in the database. This sale comes as KVYO trades at $19.14, down 49.0% from its 52-week high of $37.50, and follows a string of five prior sales at this ticker across 11 days (2026-03-10 through 2026-03-31). Over Bialecki's cross-ticker open-market history, his prior 20 sells averaged -18.5% 30-day returns and -42.8% 90-day returns, with a 100.00% well-timed rate (stocks fell after his sales), though none of his prior KVYO trades have yet reached measurable 90-day outcomes. The company itself remains unprofitable (full-year net income negative) despite 31.6% annual revenue growth, adding fundamental uncertainty to the context of these executive share dispositions.

Klaviyo Co-CEO Bialecki sells 200,000 shares ($3.6M) at $18.17; stock now $19.03, down 49.2% from $37.50 high.

Andrew Bialecki, Co-CEO of Klaviyo, sold 200,000 shares at $18.17 on 2026-03-24, totaling $3,634,000.00, reducing his holdings to 0 shares in common stock. This is part of a concentrated series of sales over the past two weeks (5 prior trades at KVYO since 2026-03-03), though the FLAG indicates this transaction involves a derivative conversion, meaning the full extent of his economic interest in the company may extend beyond the Table I common shares shown. The stock has declined 49.2% from its 52-week high of $37.50 and sits 5.0% above the transaction price. Against his cross-ticker track record of 100.00% well-timed sells (avg 90d return -40.9%), KVYO's timing outcomes are not yet measurable. The company generated $310.9M in quarterly revenue with +31.6% annual growth but remains unprofitable, posting a net loss of $426.0K in the most recent full fiscal year. Given the high visibility of executive stock sales and the ongoing unprofitability despite strong revenue growth, this concentrated liquidation in common shares—paired with recent derivative conversion activity—warrants investor attention.

Co-CEO Bialecki sells entire common-share position: 200,000 shares for $3.9M at $19.37 avg; stock now -50.2% from 52-week high.

Andrew Bialecki, Co-Chief Executive Officer of Klaviyo, executed 2 separate sales totaling 200,000 shares for $3,873,820.55 on 2026-03-17, selling at $19.60 and $19.15 respectively (blended average $19.37). The form 4 carries a derivative-conversion flag indicating his real position lives in derivative holdings (Table II), so this represents a conversion and partial sale of a specific batch, not a complete stake exit. Current price of $18.67 is now -50.2% below the 52-week high of $37.50 and trading slightly above the 52-week low. The timing is notable: Bialecki has a cross-ticker track record of 20 prior open-market sells with a 100.00% well-timed rate (90-day negative returns), yet at Klaviyo specifically, his 5 prior transactions remain unmeasured pending outcome data. The company posted $310,880,000.00 in latest quarter revenue and +31.6% annual revenue growth, but remains unprofitable with $-426,000.00 in net income over the most recent full fiscal year, which may inform near-term positioning decisions by the co-executive.

Klaviyo Co-CEO Bialecki sells 206,827 shares for $4,127,832.92; holds zero shares post-transaction from derivative conversion.

Bialecki executed 2 separate sales totaling 206,827 shares for $4,127,832.92 on 2026-03-10, with a blended average price of $19.96. The filing contains a derivative-conversion transaction; the insider's position includes Table II derivative securities not yet populated in the database, so these sales represent a partial liquidation of a specific share batch rather than a complete exit. Against a 52-week high of $37.50, the stock is trading -48.6% from peak at the current price of $19.27, and has declined -35.4% over 90 days. The company generated $310,880,000 in latest-quarter revenue with +31.6% annual growth but remains unprofitable (full-year net income was negative). While Bialecki's cross-ticker track record shows a 100% well-timed rate on 20 prior sells (avg 90d return -32.0%), his prior trades at KVYO have not yet produced measurable 90-day outcomes, and his most recent KVYO sale (2026-01-27) showed -27.1% return at the 30-day mark. The sequence of five KVYO sales over the past 6 weeks, culminating in this 206.8K share reduction, against deteriorating stock performance and company unprofitability, merits closer examination of the underlying motivations and derivative position structure.

KVYO co-CEO Bialecki sells entire 200.0K share stake (200K shares for $3.7M) via 2 transactions at $18.86 and $17.90

Andrew Bialecki, Co-Chief Executive Officer, executed 2 separate sales totaling 200,000 shares for $3,727,861.12 on March 3, 2026, at blended average price of $18.64 per share. The filing contains a derivative-conversion flag indicating the Table I holdings reflect a conversion of derivative securities; the insider's full position cannot be determined from Table I alone and may include unrealized derivative holdings not yet populated in our database. At current price of $21.18, the sold shares are trading 13.6% higher than the transaction prices, suggesting unfavorable near-term timing on this execution. Against his cross-ticker track record of 20 prior sells with 100.00% well-timed rate at the 90-day mark, this sale occurs in a divergent context: at Klaviyo specifically, his prior 5 trades show 0 well-timed outcomes measurable to date, with recent same-ticker sales (Jan 20, Jan 27, Feb 24) posting 30-day declines of -24.9%, -27.1%, and -25.9% respectively. The underlying company remains unprofitable (full-year net income negative) despite strong 31.6% annual revenue growth, which provides a fundamental backdrop for insider disposition activity.